How many drugs treat Liver cell carcinoma?

Drug Landscape tracks 10 marketed treatments for Liver cell carcinoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/liver-cell-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Liver cell carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liver cell carcinoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Liver cell carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Imjudo	TREMELIMUMAB	AstraZeneca	CTLA-4-directed Blocking Antibody [EPC]	CTLA-4	2022-01-01
Imfinzi	durvalumab	AstraZeneca	Programmed Death Ligand-1 Blocker [EPC]	Programmed cell death 1 ligand 1	2017-01-01
Tecentriq	atezolizumab	Roche	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death 1 ligand 1	2016-01-01
Lenvima	LENVATINIB	Eisai	Kinase Inhibitor [EPC]	Proto-oncogene tyrosine-protein kinase receptor Ret	2015-01-01
Cyramza	RAMUCIRUMAB	Eli Lilly	Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]	Vascular endothelial growth factor receptor 2	2014-01-01
Stivarga	regorafenib	Bayer	Kinase Inhibitor	Bifunctional epoxide hydrolase 2	2012-01-01
Cometriq	Cabometyx	Exelixis	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Cometriq	CABOZANTINIB	Exelixis Inc	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Nexavar	SORAFENIB	Bayer	Kinase Inhibitor [EPC]	Vascular endothelial growth factor receptor 2	2005-01-01
Bevacizumab	Bevacizumab-Bvzr	Roche	Monoclonal antibody	Vascular Endothelial Growth Factor (VEGF)	2004-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 3 drugs in Liver cell carcinoma
Bayer · 2 drugs in Liver cell carcinoma
AstraZeneca · 2 drugs in Liver cell carcinoma
Exelixis · 1 drug in Liver cell carcinoma
Exelixis Inc · 1 drug in Liver cell carcinoma
Fujian Medical University · 1 drug in Liver cell carcinoma
University Medical Center Groningen · 1 drug in Liver cell carcinoma
ASTRAZENECA AB · 1 drug in Liver cell carcinoma
Washington University School of Medicine · 1 drug in Liver cell carcinoma
Eisai · 1 drug in Liver cell carcinoma
Eli Lilly · 1 drug in Liver cell carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Liver cell carcinoma:

Cite this brief

Drug Landscape (2026). Liver cell carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/liver-cell-carcinoma. Accessed 2026-06-10.

Liver cell carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing